Neuren receives US$100 million initial payment for expanded DAYBUE agreement

July 27, 2023 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Australian company Neuren Pharmaceuticals (ASX:NEU) has received the upfront payment of US$100 million that was earned following the recent global expansion of its partnership with Acadia Pharmaceuticals for DAYBUE (trofinetide). …

Subscribe now to continue reading.

Latest Video

Pfizer clinches Metsera, reshaping the balance in global obesity therapy race
November 11, 2025 - Latest News
CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'
November 11, 2025 - Latest News
New Zealand accelerates medicines reform with major regulatory changes
November 12, 2025 - Latest News
Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'
November 11, 2025 - Latest News
'AI Must Be trusted, transparent, and integrated in the future of health technology assessment'
November 11, 2025 - Latest News

Neuren receives US$100 million initial payment for expanded DAYBUE agreement

This is a preview of subscriber content

Latest Video

Most Read

Pfizer clinches Metsera, reshaping the balance in global obesity therapy race

CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'

New Zealand accelerates medicines reform with major regulatory changes

Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'

'AI Must Be trusted, transparent, and integrated in the future of health technology assessment'

New Stories

Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity

PYC Therapeutics appoints Peter Coleman as new Chair as part of board renewal

New gene discoveries improve diagnosis of inherited heart disease

Chimeric Therapeutics reports strong early results from CHM CDH17 Phase 1/2 trial

Australia joins global WHO task force to tackle antimicrobial resistance

New post-market review workplan focuses on real-world data and patient outcomes

Government adds new first-line treatment to the PBS for deadly blood cancer

Sign In

Neuren receives US$100 million initial payment for expanded DAYBUE agreement

This is a preview of subscriber content

Latest Video

Most Read

Pfizer clinches Metsera, reshaping the balance in global obesity therapy race

CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'

New Zealand accelerates medicines reform with major regulatory changes

Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'

'AI Must Be trusted, transparent, and integrated in the future of health technology assessment'

Follow Us

New Stories

Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity

PYC Therapeutics appoints Peter Coleman as new Chair as part of board renewal

New gene discoveries improve diagnosis of inherited heart disease

Chimeric Therapeutics reports strong early results from CHM CDH17 Phase 1/2 trial

Australia joins global WHO task force to tackle antimicrobial resistance

New post-market review workplan focuses on real-world data and patient outcomes

Government adds new first-line treatment to the PBS for deadly blood cancer